Autopsy report · NCT04672564

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

“sponsor strategy change”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 1 month before it stopped.
• 93 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Shenyang Tonglian Group CO., Ltd

Sponsor type

Industry

Conditions

Coronavirus Disease 2019

Interventions

Carrimycin; Placebo

Participants

93

Sites

17

Countries

Argentina, Brazil, Mexico, Philippines, Ukraine, United States

Trials that died the same way

• POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
  “Change in Sponsor strategy” (98% match in meaning)
• A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
  “Sponsor Strategy” (92% match in meaning)
• Effects of Dietary Supplements on Nail and Hair Health
  “Strategic change by sponsor” (90% match in meaning)
• Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
  “Strategic direction of the sponsor changed” (90% match in meaning)
• Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-1816 in Healthy Subjects
  “Sponsor internal strategy change.” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.